Together, these findings support that in addition to the MYC-enriched and KRAS-enriched programs, microenvironmental pressures can also drive dynamic changes in regional biology of GBM that may blunt or alter their sensitivity to therapeutic agents (Fig. 6f). The gene discussed is KRAS; the disease is glioblastoma.